Getting medicines to those who need them most

We recognize that the patients and families affected by life-threatening diseases anxiously await more effective medicines with each passing day. Knowing this drives us to work harder to deliver transformative treatments more swiftly.

We also seek to ensure any medicine we develop is safe and effective and follows the rigorous guidelines established by regulatory agencies.

We strive to balance these two complementary and vital goals in all that we do.

Our clinical trials

Our clinical trials in

Systemic mastocytosis (SM)

Trial Phase

Trial Phase 2

Target Population

Target Population

Aggressive SM, SM with associated hematologic neoplasm and mast cell leukemia

Study Status

Study Status

Active, fully enrolled

ClinicalTrials.gov
Study Number

Study Number

NCT03580655

Trial Phase

Trial Phase 2

Target Population

Target Population

Indolent SM

Study Status

Study Status

Active, fully enrolled

ClinicalTrials.gov
Study Number

Study Number

NCT03731260

Trial Phase

BP_Web_3.0_Trial_2-3

Target Population

Target Population

Indolent SM

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04910685

Trial Phase

Trial Phase 1/2

Target Population

Target Population

Aggressive SM, SM with associated hematologic neoplasm, mast cell leukemia and other KIT-altered hematological malignancies

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT05609942

Our clinical trials in

CDK2-vulnerable cancers and estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer

Trial Phase

Trial Phase 1

Target Population

Target Population

Cyclin E aberrant ovarian cancer, endometrial cancer, gastric cancer and other solid tumors, and ER+, HER2- breast cancer

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT05252416

Our clinical trials in

Pediatric cancers

Trial Phase

Trial Phase 1/2

Target Population

Target Population

Solid tumors with a KIT or PDGFRA mutation and gliomas with an H3K27M mutation in pediatric patients

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT04773782